EU Approves First EoE Treatment for Kids Ages 2-17

For years, children suffering from eosinophilic esophagitis have had to make do with adult medications never designed for young bodies. That changes now with Europe's approval of the first treatment made specifically for kids with this painful condition.

Eosinophilic esophagitis, or EoE, makes swallowing painful and difficult for children. The condition causes chest pain, trouble eating, and food getting stuck in the throat because inflammation damages the esophagus.

The European Medicines Agency recommended approval of Jorveza oral suspension for children and teens ages 2 to 17 in February 2026. The liquid medicine works by coating the esophagus through saliva, reducing inflammation right where it hurts.

Until now, doctors had no choice but to prescribe adult formulations to their young patients. They used medications off-label, meaning outside their approved uses, because nothing else existed for kids.

The new suspension gives parents and doctors a safer, more appropriate option. The formula delivers the right doses for smaller bodies without the guesswork of adapting adult treatments.

The Bright Side

Clinical trials showed the treatment works remarkably well. In the PEER study of 71 young patients, about half of those taking medium or high doses saw major improvements after just 12 weeks.

Kids taking the medicine showed dramatic reductions in inflammation. The high-dose group saw 90% improvement in tissue health, compared to barely 6% in the placebo group.

Side effects stayed minimal and manageable. Only 3% of participants developed oral thrush, a common and treatable issue with this type of medication. Blood pressure changes were so small they caused no problems, and importantly, the medicine didn't affect kids' growth rates.

Parents whose children struggle with painful swallowing finally have hope for real relief. The treatment should reach pharmacies across the EU within 67 days after the European Commission's final approval.

The medicine received special designations recognizing both the rarity of EoE and the urgent need for pediatric treatments. Doctors experienced in treating the condition will prescribe and monitor the therapy.

Thousands of European families who've watched their children struggle through painful meals now have a path forward designed just for them.